Enterprise Value
87.91M
Cash
272.7M
Avg Qtr Burn
N/A
Short % of Float
7.63%
Insider Ownership
20.71%
Institutional Own.
54.32%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AAV Capsids (Pfizer) Details Neurological disorder | Phase 1 Update | |
AAV Capsids (Novartis) Details Cardiovascular disease , Neurological disorder | Phase 1 Initiation | |
AAV Capsids + ZF-TRs (Sangamo) Details Prion disease | Phase 1 Initiation | |
AAV Capsids Details Cardiovascular disease , Neurological disorder | Phase 1 Initiation | |
VY-AADC (NBIb-1817) Details Parkinson's disease, Central nervous system illness | Failed Discontinued | |
VY-HTT01 Details Huntington's disease | Failed Discontinued |